Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Bisphosphonate-related osteonecrosis of the jaw in metastatic breast cancer patients: a review of 25 cases

Maxillofacial Plastic and Reconstructive Surgery 2016³â 38±Ç 1È£ p.46 ~ 46
±èÈ«ÁØ, ¹ÚÅÂÁØ, ¾È°­¹Î,
¼Ò¼Ó »ó¼¼Á¤º¸
±èÈ«ÁØ ( Kim Hong-Joon ) - University of Ulsan College of Medicine Asan Medical Center Department of Oral and Maxillofacial Surgery
¹ÚÅÂÁØ ( Park Tae-Jun ) - University of Ulsan College of Medicine Asan Medical Center Department of Oral and Maxillofacial Surgery
¾È°­¹Î ( Ahn Kang-Min ) - University of Ulsan College of Medicine Asan Medical Center Department of Oral and Maxillofacial Surgery

Abstract


Background: Intravenous bisphosphonates have been used in metastatic breast cancer patients to reduce pathologic bone fracture and bone pain. However, necrosis of the jaw has been reported in those who received intravenous bisphosphonates. Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is caused by dental extraction, dental implant surgery, and denture wearing; however, it occurs spontaneously. The purpose of this study was to report BRONJ in metastatic breast cancer patients.

Methods: Consecutive 25 female patients were referred from the Department of Oncology from 2008 to 2014 for jaw bone discomfort. Staging of breast cancer, history of bisphosphonate infusion, etiology of BRONJ, and treatment results were reviewed. Average age of the patients was 55.4 years old (38?74). Twelve maxillae and 16 mandibles were involved. Conservative treatments such as irrigation, antibiotic medication, analgesics, and oral gargle were applied for all patients for the initial treatment. Patients who had sequestrum underwent debridement and primary closure.

Results: The etiologies of BRONJ were dental extraction (19 cases), dental implant (2 cases), and endodontic treatment (1 case). However, three patients did not have any risk factors to cause BRONJ. Three patients died of progression of metastasis during follow-up periods. Surgical debridement was performed in 21 patients with success in 18 patients. Three patients showed recurred bone exposure and infection after operation.

Conclusions: Prevention of the BRONJ is critical in metastatic breast cancer patients. Conservative treatment to reduce pain, discomfort, and infection is recommended for the initial therapy. However, if there is a sequestrum, surgical debridement and primary closure is the key to treat the BRONJ.

Å°¿öµå

Bisphosphonate; Breast cancer; Bisphosphonate-related osteonecrosis of the jaw (BRONJ); Extraction; Dental implant

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed